Sirolimus in Treating Patients With HIV-Related Kaposi's Sarcoma
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as sirolimus, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Sirolimus also may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth and by blocking blood flow to the tumor.
PURPOSE: This pilot study is studying sirolimus in treating patients with HIV-related
Kaposi's sarcoma.
Phase:
Phase 1
Details
Lead Sponsor:
AIDS Malignancy Consortium
Collaborators:
National Cancer Institute (NCI) The Emmes Company, LLC The EMMES Corporation